Eaton Vance Management’s Intellia Therapeutics NTLA Stock Holding History

Eaton Vance Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$560K	Hold	10,009	–	–	﹤0.01%	1327
2022 Q2	$518K	Sell	10,009 -1,000	-9%	-$50.8K	﹤0.01%	1366
2022 Q1	$800K	Hold	11,009	–	–	﹤0.01%	1417
2021 Q4	$1.3M	Hold	11,009	–	–	﹤0.01%	1125
2021 Q3	$1.34M	Hold	11,009	–	–	﹤0.01%	1014
2021 Q2	$1.78M	Buy	11,009 +308	+3%	+$24K	﹤0.01%	1039
2021 Q1	$859K	Buy	+10,701	New	+$718K	﹤0.01%	1162

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Eaton Vance Management's NTLA Position: Q3 2022 in Review

Eaton Vance Management held its Intellia Therapeutics (NTLA) position steady in Q3 2022 at 10,009 shares worth $560K. The position accounts for ﹤0.01% of the portfolio, ranked #1327.

Eaton Vance Management first reported a position in NTLA in Q1 2021 and has held it in 7 quarters since. The position peaked at $1.78M in Q2 2021. 319 funds tracked by Wall St. Rank hold NTLA as of Q3 2022.

Eaton Vance Management held 10,009 shares of Intellia Therapeutics worth $560K as of Q3 2022.
Eaton Vance Management left its Intellia Therapeutics share count unchanged in Q3 2022.
Intellia Therapeutics made up ﹤0.01% of Eaton Vance Management's portfolio in Q3 2022, its #1327 holding.
Eaton Vance Management first reported a position in Intellia Therapeutics in Q1 2021 and has held it in 7 quarters since.
Eaton Vance Management's Intellia Therapeutics position peaked at $1.78M in Q2 2021.
319 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2022.

Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.